Literature DB >> 3696778

Comparative study on the infection rates of different Glossina species for East and West African Trypanosoma vivax stocks.

S K Moloo1, S B Kutuza, J Desai.   

Abstract

Teneral male Glossina morsitans centralis, G. austeni, G. palpalis palpalis, G. p. gambiensis, G. fuscipes fuscipes, G. tachinoides and G. brevipalpis were fed on the flanks of Boran calves infected with Trypanosoma vivax stock ILRAD 2241 isolated from a cow in Likoni, Kenya; stock ILRAD 2337 isolated from a cow in Galana, Kenya; stock ILRAD 1392 isolated from a cow in Nigeria; or, stock EATRO 1721 isolated from G. m. submorsitans in Nigeria. The tsetse were fed on the infected hosts for 24 days and were then dissected to determine the infection rates. In G. m. centralis and G. brevipalpis, the mature infection rates of T. vivax from Kenya were 61.1%, and 75.3% for ILRAD 2241, and 36.2% and 58.2% for ILRAD 2337, respectively. In G. austeni and in the four palpalis group of tsetse, the rates for these two stocks were very low and ranged from 0% in G. p. palpalis to 1.8% in G. austeni for ILRAD 2241 and from 0% in G. f. fuscipes to 5% in G. tachinoides for ILRAD 2337. In contrast, the hypopharyngeal infection rates of T. vivax from Nigeria were quite high in all the 7 tsetse species and sub-species. They ranged from 55.5% in G. austeni to 91.9% in G. p. gambiensis for ILRAD 1392, and from 71.4% in G. austenei to 97.1% in G. brevipalpis for EATRO 1721.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 3696778     DOI: 10.1017/s0031182000057966

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  7 in total

Review 1.  The origins of the trypanosome genome strains Trypanosoma brucei brucei TREU 927, T. b. gambiense DAL 972, T. vivax Y486 and T. congolense IL3000.

Authors:  Wendy Gibson
Journal:  Parasit Vectors       Date:  2012-04-07       Impact factor: 3.876

2.  Factors associated with persistence of African animal trypanosomiasis in Lango subregion, northern Uganda.

Authors:  Robert Mandela Wangoola; Bardosh Kevin; Christine Among Acup; Susan Welburn; Charles Waiswa; James Bugeza
Journal:  Trop Anim Health Prod       Date:  2019-05-03       Impact factor: 1.559

3.  Trypanosoma vivax infections: pushing ahead with mouse models for the study of Nagana. I. Parasitological, hematological and pathological parameters.

Authors:  Nathalie Chamond; Alain Cosson; Marie Christine Blom-Potar; Grégory Jouvion; Simon D'Archivio; Mathieu Medina; Sabrina Droin-Bergère; Michel Huerre; Sophie Goyard; Paola Minoprio
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10

4.  Genetic engineering of Trypanosoma (Dutonella) vivax and in vitro differentiation under axenic conditions.

Authors:  Simon D'Archivio; Mathieu Medina; Alain Cosson; Nathalie Chamond; Brice Rotureau; Paola Minoprio; Sophie Goyard
Journal:  PLoS Negl Trop Dis       Date:  2011-12-27

5.  New insights from Gorongosa National Park and Niassa National Reserve of Mozambique increasing the genetic diversity of Trypanosoma vivax and Trypanosoma vivax-like in tsetse flies, wild ungulates and livestock from East Africa.

Authors:  Carla Mf Rodrigues; Herakles A Garcia; Adriana C Rodrigues; André G Costa-Martins; Carlos L Pereira; Dagmar L Pereira; Zakaria Bengaly; Luis Neves; Erney P Camargo; Patrick B Hamilton; Marta Mg Teixeira
Journal:  Parasit Vectors       Date:  2017-07-17       Impact factor: 3.876

Review 6.  A systematic review and meta-analysis of trypanosome prevalence in tsetse flies.

Authors:  Reta D Abdi; Getahun E Agga; Weldegebrial G Aregawi; Merga Bekana; Thomas Van Leeuwen; Vincent Delespaux; Luc Duchateau
Journal:  BMC Vet Res       Date:  2017-04-13       Impact factor: 2.741

7.  Genetic diversity among Trypanosoma (Duttonella) vivax strains from Zambia and Ghana, based on cathepsin L-like gene.

Authors:  Jesca Nakayima; Ryo Nakao; Andy Alhassan; Kyoko Hayashida; Boniface Namangala; Charles Mahama; Kofi Afakye; Chihiro Sugimoto
Journal:  Parasite       Date:  2013-07-01       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.